# Safety of IFNa Kinoid in Systemic Lupus Erythematosus

> **NCT01058343** · PHASE1,PHASE2 · COMPLETED · sponsor: **Neovacs** · enrollment: 28 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** IFN-K

## Key facts

- **NCT ID:** NCT01058343
- **Lead sponsor:** Neovacs
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2011-04
- **Final completion:** 2016-06
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2019-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01058343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01058343, "Safety of IFNa Kinoid in Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01058343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*